BioSpace News Archive

Drug Development

Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486

Bristol-Myers Squibb is looking to start 2020 on the right foot by filing a New Drug Application for its acute myeloid leukemia treatment CC-486 after data shows the medication extends survival time for AML patients.

December 10, 2019
·
2 min read
·
Alex Keown
Drug Development

Top 10 Clinical Trial Indications in the Bay State

BioSpace put together a list of the top 10 indications being researched in the area by pharma companies, academic institutions and other organizations.

December 10, 2019
·
3 min read
·
Alex Keown
Biotech Bay

GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage

A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients.

December 10, 2019
·
3 min read
·
Alex Keown
Business

Truvian Sciences Moves Closer to Commercialization of Benchtop Blood Testing System

“We still have some work in front of us, but we’re happy where we are,” said Jeff Hawkins, CEO of Truvian Sciences.

December 10, 2019
·
3 min read
·
Alex Keown